249 related articles for article (PubMed ID: 21878623)
1. Allosteric and orthosteric sites in CC chemokine receptor (CCR5), a chimeric receptor approach.
Thiele S; Steen A; Jensen PC; Mokrosinski J; Frimurer TM; Rosenkilde MM
J Biol Chem; 2011 Oct; 286(43):37543-54. PubMed ID: 21878623
[TBL] [Abstract][Full Text] [Related]
2. Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.
Lau G; Labrecque J; Metz M; Vaz R; Fricker SP
J Biol Chem; 2015 Apr; 290(17):11041-51. PubMed ID: 25767113
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanism of Action for Allosteric Modulators and Agonists in CC-chemokine Receptor 5 (CCR5).
Karlshøj S; Amarandi RM; Larsen O; Daugvilaite V; Steen A; Brvar M; Pui A; Frimurer TM; Ulven T; Rosenkilde MM
J Biol Chem; 2016 Dec; 291(52):26860-26874. PubMed ID: 27834679
[TBL] [Abstract][Full Text] [Related]
4. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
[TBL] [Abstract][Full Text] [Related]
5. Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5.
Hall SE; Mao A; Nicolaidou V; Finelli M; Wise EL; Nedjai B; Kanjanapangka J; Harirchian P; Chen D; Selchau V; Ribeiro S; Schyler S; Pease JE; Horuk R; Vaidehi N
Mol Pharmacol; 2009 Jun; 75(6):1325-36. PubMed ID: 19297521
[TBL] [Abstract][Full Text] [Related]
6. Partial Agonist and Biased Signaling Properties of the Synthetic Enantiomers J113863/UCB35625 at Chemokine Receptors CCR2 and CCR5.
Corbisier J; Huszagh A; Galés C; Parmentier M; Springael JY
J Biol Chem; 2017 Jan; 292(2):575-584. PubMed ID: 27895119
[TBL] [Abstract][Full Text] [Related]
7. CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis.
Raghu H; Lepus CM; Wang Q; Wong HH; Lingampalli N; Oliviero F; Punzi L; Giori NJ; Goodman SB; Chu CR; Sokolove JB; Robinson WH
Ann Rheum Dis; 2017 May; 76(5):914-922. PubMed ID: 27965260
[TBL] [Abstract][Full Text] [Related]
8. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor.
Watson C; Jenkinson S; Kazmierski W; Kenakin T
Mol Pharmacol; 2005 Apr; 67(4):1268-82. PubMed ID: 15644495
[TBL] [Abstract][Full Text] [Related]
9. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
[TBL] [Abstract][Full Text] [Related]
10. Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists.
Zheng Y; Qin L; Zacarías NV; de Vries H; Han GW; Gustavsson M; Dabros M; Zhao C; Cherney RJ; Carter P; Stamos D; Abagyan R; Cherezov V; Stevens RC; IJzerman AP; Heitman LH; Tebben A; Kufareva I; Handel TM
Nature; 2016 Dec; 540(7633):458-461. PubMed ID: 27926736
[TBL] [Abstract][Full Text] [Related]
11. Extracellular disulfide bridges serve different purposes in two homologous chemokine receptors, CCR1 and CCR5.
Rummel PC; Thiele S; Hansen LS; Petersen TP; Sparre-Ulrich AH; Ulven T; Rosenkilde MM
Mol Pharmacol; 2013 Sep; 84(3):335-45. PubMed ID: 23765404
[TBL] [Abstract][Full Text] [Related]
12. Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor.
Saita Y; Kondo M; Shimizu Y
Int Immunopharmacol; 2007 Dec; 7(12):1528-34. PubMed ID: 17920529
[TBL] [Abstract][Full Text] [Related]
13. Positive versus negative modulation of different endogenous chemokines for CC-chemokine receptor 1 by small molecule agonists through allosteric versus orthosteric binding.
Jensen PC; Thiele S; Ulven T; Schwartz TW; Rosenkilde MM
J Biol Chem; 2008 Aug; 283(34):23121-8. PubMed ID: 18559339
[TBL] [Abstract][Full Text] [Related]
14. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5.
Andrews G; Jones C; Wreggett KA
Mol Pharmacol; 2008 Mar; 73(3):855-67. PubMed ID: 18042736
[TBL] [Abstract][Full Text] [Related]
15. Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists.
Carter PH; Tebben AJ
Methods Enzymol; 2009; 461():249-79. PubMed ID: 19480923
[TBL] [Abstract][Full Text] [Related]
16. Key determinants of selective binding and activation by the monocyte chemoattractant proteins at the chemokine receptor CCR2.
Huma ZE; Sanchez J; Lim HD; Bridgford JL; Huang C; Parker BJ; Pazhamalil JG; Porebski BT; Pfleger KDG; Lane JR; Canals M; Stone MJ
Sci Signal; 2017 May; 10(480):. PubMed ID: 28536301
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for chemokine recognition and receptor activation of chemokine receptor CCR5.
Zhang H; Chen K; Tan Q; Shao Q; Han S; Zhang C; Yi C; Chu X; Zhu Y; Xu Y; Zhao Q; Wu B
Nat Commun; 2021 Jul; 12(1):4151. PubMed ID: 34230484
[TBL] [Abstract][Full Text] [Related]
18. [Viral entry as therapeutic target. Current situation of entry inhibitors].
Arenzana-Seisdedos F
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
[TBL] [Abstract][Full Text] [Related]
19. Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
Seibert C; Ying W; Gavrilov S; Tsamis F; Kuhmann SE; Palani A; Tagat JR; Clader JW; McCombie SW; Baroudy BM; Smith SO; Dragic T; Moore JP; Sakmar TP
Virology; 2006 May; 349(1):41-54. PubMed ID: 16494916
[TBL] [Abstract][Full Text] [Related]
20. Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity.
Paterlini MG
Biophys J; 2002 Dec; 83(6):3012-31. PubMed ID: 12496074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
